DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Nab-paclitaxel Versus Topotecan As Second-Line Treatment for Patients With Extensive Stage Small Cell Lung Cancer

Phase 2

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: nab-paclitaxel
Drug: Topotecan

First Posted Date: 2019-12-30

Last Posted Date: 2019-12-30

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 386

Registration Number: NCT04213937

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

Phase 2

Completed

Conditions: Chemoradiotherapy
Esophageal Cancer
Unresectable Malignant Neoplasm
Nimotuzumab

Interventions: Radiation: Radiotherapy
Drug: Nimotuzumab
Drug: S-1

First Posted Date: 2019-12-23

Last Posted Date: 2024-05-16

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 55

Registration Number: NCT04207918

Locations: 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China

Mediastinoscopy-assisted Transhiatal Esophagectomy Versus Thoraco-laparoscopic Esophagectomy for Esophageal Cancer

Not Applicable

Conditions: Esophageal Neoplasms

Interventions: Procedure: Thoraco-laparoscopic esophagectomy
Procedure: Mediastinoscopy-assisted transhiatal esophagectomy

First Posted Date: 2019-10-14

Last Posted Date: 2020-04-15

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 160

Registration Number: NCT04125849

Locations: 🇨🇳
Cancer Hospital of Chinese Academy of Medical Sciences Shenzhen Center, Shenzhen, Guangdong, China

Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma

Phase 2

Conditions: Muscle-invasive Bladder Cancer
Upper Tract Urinary Carcinoma

Interventions: Drug: Toripalimab

First Posted Date: 2019-09-23

Last Posted Date: 2022-03-29

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 64

Registration Number: NCT04099589

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Taxane Induced Peripheral Neuropathy in Chinese Patients With Breast Cancer

Conditions: Breast Cancer

Interventions: Other: Patient Questionnaires
Other: Blood Collection

First Posted Date: 2019-08-28

Last Posted Date: 2020-03-30

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 500

Registration Number: NCT04068090

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection

Phase 2

Conditions: Hepatocellular Carcinoma

Interventions: Procedure: Hepatic Arterial Infusion(HAI)
Combination Product: Apatinib Mesylate +SHR-1210

First Posted Date: 2019-02-15

Last Posted Date: 2019-02-15

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 200

Registration Number: NCT03839550

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With Advanced Triple-negative Breast Cancer

Phase 2

Conditions: Triple-negative Breast Cancer

Interventions: Drug: Apatinib
Drug: capecitabine

First Posted Date: 2018-12-14

Last Posted Date: 2018-12-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 80

Registration Number: NCT03775928

Locations: 🇨🇳
Cancer hospital, ChineseAMS, Beijing, Beijing, China

Diagnostic Significance of CTCs in Patients With Thyroid Nodules (Circulating Tumor Cells)

Not Applicable

Conditions: Thyroid Nodule
Diagnoses Disease

Interventions: Diagnostic Test: circulating tumor cells test
Diagnostic Test: Fine needle aspiration biopsy

First Posted Date: 2018-12-11

Last Posted Date: 2019-09-17

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 200

Registration Number: NCT03772496

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Science, Beijing, Beijing, China

MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy for Unresectable Rectal Cancer

Phase 2

Recruiting

Conditions: Rectal Neoplasms

Interventions: Radiation: SCPRT
Radiation: CRT
Drug: CAPOX

First Posted Date: 2018-10-22

Last Posted Date: 2024-05-29

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 200

Registration Number: NCT03714490

Locations: 🇨🇳
Department of Radiation Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Combine TACE and Autologous Tcm Immunotherapy Versus TACE Alone for HCC With MVI After Radical Resection

Phase 2

Completed

Conditions: Hepatocellular Carcinoma
Malignant Neoplasm

Interventions: Combination Product: TACE plus autologous Tcm immunotherapy
Procedure: TACE

First Posted Date: 2018-07-03

Last Posted Date: 2020-06-11

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 52

Registration Number: NCT03575806

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy